4
Changes in Ownership
Serina Therapeutics, Inc. Filed Acc 0001301120-26-000004
Chief Scientific Officer sold 6,500 shares at an average $2.50 ($16,253)
- Chief Scientific Officer acquired 6,500 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Moreadith Randall · Chief Scientific Officer
Table I: Non-derivative
4 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2026-01-13 | Exercise or conversion : show line 1 in the form 10b5-1 | +5,416 | $0.06 | $325 | 5,416 | D |
| 2026-01-13 | Sale : show line 2 in the form 10b5-1 | −5,416 | $2.50 | $13,540 | 0 | D |
| 2026-01-14 | Exercise or conversion : show line 3 in the form 10b5-1 | +1,084 | $0.06 | $65 | 1,084 | D |
| 2026-01-14 | Sale : show line 4 in the form 10b5-1 | −1,084 | $2.50 | $2,713 | 0 | D |
| Open-market sales · 6,500 sh · avg $2.50 · $16,253 | ||||||
Table II: Derivative
2 lines| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2026-01-13 | Exercise or conversion : show line 5 in the form 10b5-1 Stock Option (right to buy) | −5,416 | 333,770 | D |
| 2026-01-14 | Exercise or conversion : show line 6 in the form 10b5-1 Stock Option (right to buy) | −1,084 | 332,686 | D |
Loading xslF345X05/wk-form4_1768413405.xml…